Skip to content
Alligator Bioscience
Search
Search
Se
Startpage
About Alligator
Board of Directors
Management
Career
Research and development
Immunotherapy of cancer
Pipeline
Mitazalimab
Neo-X-Prime
TM
ALG.APV-527
ATOR-1017
Research projects
Scientific publications
Technology platform
Alligator-GOLD
®
Alligator-FAB
TM
FIND
®
Scientific advisors
Corporate governance
General meeting
Board of Directors and Management
Nomination Committee
Audit Committee
Remuneration Committee
Remuneration
Auditors
Articles of association
Internal control
Investors
Share and owner information
Sharegraph
Analysts
Preferential Rights Issue Q4 2021
Preferential Rights Issue Q1 2021
IPO
Financial reports
Interim reports
Year End Reports
Annual reports
Financial calendar
Business Development
News
Press releases
Contact
Startpage
Subscribe
Key downloads
Alligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business update
Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022
Interim report January–March 2022
Alligator Bioscience publishes Annual Report for 2021
Subscribe
Updated 2022-07-15
Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our
cookie policy.
Settings
Accept all
Cookies
Do your settings below. Or read our
cookie policy.
Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save
Accept all